nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.01.2003 | Review Article

Adverse Cutaneous Reactions to Mood Stabilizers

verfasst von: Dr Julia K. Warnock, David W. Morris

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Abstract

Of all the psychotropic medications currently available, the mood-stabilizing agents have the highest incidence of severe and life-threatening adverse cutaneous drug reactions (ACDRs).

An exanthematous eruption in a patient treated with a mood-stabilizing agent should be viewed as possibly being the initial symptom of a severe and life-threatening ACDR, such as a hypersensitivity reaction, Stevens- Johnson syndrome, or toxic epidermal necrolysis. The combination of mood-stabilizing agents may increase the risk of such reactions. The mood-stabilizing agents addressed in this article are carbamazepine, lithium carbonate, valproic acid, topiramate, lamotrigine, gabapentin, and oxcarbazepine.

Prior to the initiation of a mood stabilizer, the potential benefits, risks, and adverse effects should be communicated to the patient. If possible, slow dose escalation should be attempted by the physician. Patients should also be advised to seek medical attention if they suspect a drug-induced skin reaction. If the physician suspects a severe ACDR, the offending agent should be removed immediately.

Use of tradenames is for product identification only and does not imply endorsement.

Warnock J.K., Morris D.W. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002; 3 (9): 629–636PubMedCrossRef

Culy C.R., Goa K.L. Lamotrigine: a review of its use in childhood epilepsy. Paediatr Drugs 2000 Jul; 2 (4): 299–330PubMedCrossRef

Messenheimer J.A., Giorgi L., Risner M.E. The tolerability of lamotrigine in children. Drug Saf 2000 Apr; 22 (4): 303–312PubMedCrossRef

Schaub N., Bircher A.J. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000 Feb; 55 (2): 191–193PubMedCrossRef

Yalcin B., Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 2000 Nov; 43 (5 Pt 2): 898–899PubMedCrossRef

Guberman A.H., Besag F.M., Brodie M.J., et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999 Jul; 40 (7): 985–991PubMedCrossRef

Schlienger R.G., Shapiro L.E., Shear N.H. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 3939: S22–S26CrossRef

Page R.L., O’Neil M.G., Yarbrough D.R., et al. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998 Mar; 18 (2): 392–398PubMed

Sachs B., Ronnau A.C., von Schmiedeberg S., et al. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997; 195 (1): 60–64PubMedCrossRef

10.

Li L.M., Russo M., O’Donoghue M.F., et al. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr 1996 Mar; 54 (1): 47–49PubMedCrossRef

11.

Troost R.J., Van Parys J.A., Hooijkaas H., et al. Allergy to carbamazepine: parallel in vivo and in vitro detection. Epilepsia 1996 Nov; 37 (11): 1093–1099PubMedCrossRef

12.

Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35 Suppl. 3: S23–S25PubMedCrossRef

13.

Beran R.G. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993 Jan; 34 (1): 163–165PubMedCrossRef

14.

Medical Economics staff, editors. Physician’s desk reference. 55th ed. Montvale (NJ): Medical Economics, 2001

15.

Perry P.J., Alexander B., Liskow B.I. Psychotropic drug handbook. 7th ed. Washington, DC: American Psychiatric Press, 1997

16.

Welykyj S., Gradini R., Nakao J., et al. Carbamazepine-induced eruption histologically mimicking mycosis fungoides. J Cutan Pathol 1990 Apr; 17 (2): 111–116PubMedCrossRef

17.

Roberts D.L., Marks R. Skin reactions to carbamazepine. Arch Dermatol 1981 May; 117 (5): 273–275PubMedCrossRef

18.

Hyson C., Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997 Aug; 24 (3): 245–249PubMed

19.

Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993 Nov; 29 (5): 254–257PubMedCrossRef

20.

Konishi T., Naganuma Y., Hongo K., et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993 Jul; 152 (7): 605–608PubMedCrossRef

21.

Atkin S.L., McKenzie T.M., Stevenson C.J. Carbamazepine-induced lichenoid eruption. Clin Exp Dermatol 1990 Sep; 15 (5): 382–383PubMedCrossRef

22.

Fitzpatrick T.B., Johnson R.A., Wolff K., Suurmond D. Color atlas and synopsis of clinical dermatology: common and serious diseases. 4th ed. New York: McGraw-Hill, 2001

23.

Brenner S., Wolf R., Landau M., et al. Psoriasiform eruption induced by anticonvulsants. Isr J Med Sci 1994 Apr; 30 (4): 283–286PubMed

24.

Gebauer K., Holgate C., Navaratnam A. Toxic pustuloderma: a drug induced pustulating glandular fever-like syndrome. Australas J Dermatol 1990; 31 (2): 89–93PubMedCrossRef

25.

Commens C.A., Fischer G.O. Toxic pustuloderma following carbamazepine therapy. Arch Dermatol 1988 Feb; 124 (2): 178–179PubMedCrossRef

26.

Dooley J., Camfield P., Gordon K., et al. Lamotrigine-induced rash in children. Neurology 1996 Jan; 46 (1): 240–242PubMedCrossRef

27.

Wong I.C., Mawer G.E., Sander J.W. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001 Feb; 42 (2): 237–244PubMedCrossRef

28.

Wong I.C., Mawer G.E., Sander J.W. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999 Oct; 33 (10): 1037–1042PubMedCrossRef

29.

Richens A. Safety of lamotrigine. Epilepsia 1994; 3535: S37–S40CrossRef

30.

Sander J.W., Trevisol-Bittencourt P.C., Hart Y.M., et al. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990 Dec; 7 (3): 226–229PubMedCrossRef

31.

Srebrnik A., Hes J.P., Brenner S. Adverse cutaneous reactions to psychotropic drugs. Acta Derm Venereol 1991; 158: 3–12

32.

Ghadirian A.M., Lalinec-Michaud M. Report of a patient with lithium-related alopecia and psoriasis. J Clin Psychiatry 1986 Apr; 47 (4): 212–213PubMed

33.

Natsch S., Hekster Y.A., Keyser A., et al. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 1997 Oct; 17 (4): 228–240PubMedCrossRef

34.

Fitton A., Goa K.L. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995 Oct; 50 (4): 691–713PubMedCrossRef

35.

Srebrnik A., Bar-Nathan E.A., Ilie B., et al. Vaginal ulcerations due to lithium carbonate therapy. Cutis 1991 Jul; 48 (1): 65–66PubMed

36.

Hogan D.J., Murphy F., Burgess W.R., et al. Lichenoid stomatitis associated with lithium carbonate. J Am Acad Dermatol 1985 Aug; 13 (2 Pt 1): 243–246PubMedCrossRef

37.

Bublin J.G., Thompson D.F. Drug-induced hair color changes. J Clin Pharm Ther 1992 Oct; 17 (5): 297–302PubMedCrossRef

38.

Bittencourt P.R. Valproic acid, curly hair and weight gain. Arq Neuropsiquiatr 1986 Mar; 44 (1): 78–81PubMed

39.

Gupta A.K. ’Perming’ effects associated with chronic valproate therapy. Br J Clin Pract 1988 Feb; 42 (2): 75–77PubMed

40.

Jeavons P.M., Clark J.E., Harding G.F. Valproate and curly hair [letter]. Lancet 1977 Feb 12; I (8007): 359CrossRef

41.

Miranda-Romero A., Perez-Oliva N., Aragoneses H., et al. Carbamazepine hypersensitivity syndrome mimicking mycosis fungoides. Cutis 2001 Jan; 67 (1): 47–51PubMed

42.

Lombardi S.M., Girelli D.G., Corrocher R. Severe multisystemic hypersensitivity reaction to carbamazepine including dyserythropoietic anemia. Ann Pharmacother 1999 May; 33 (5): 571–575PubMedCrossRef

43.

Schlienger R.G., Shear N.H. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39 Suppl. 7: S3–S7PubMedCrossRef

44.

Tennis P., Stern R.S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997 Aug; 49 (2): 542–546PubMedCrossRef

45.

Troost R.J., Oranje A.P., Lijnen R.L., et al. Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Pediatr Dermatol 1996 Jul; 13 (4): 316–320PubMedCrossRef

46.

Okuyama R., Ichinohasama R., Tagami H. Carbamazepine induced erythroderma with systemic lymphadenopathy. J Dermatol 1996 Jul; 23 (7): 489–494PubMed

47.

De Vriese A.S., Philippe J., Van Renterghem D.M., et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995 May; 74 (3): 144–151CrossRef

48.

Vittorio C.C., Muglia J.J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995 Nov 27; 155 (21): 2285–2290PubMedCrossRef

49.

Scerri L., Shall L., Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome: pathogenic and diagnostic considerations. Clin Exp Dermatol 1993 Nov; 18 (6): 540–542PubMedCrossRef

50.

Horneff G., Lenard H.G., Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics 1992 Oct; 23 (5): 272–275PubMedCrossRef

51.

Robbie M.J., Scurry J.P., Stevenson P. Carbamazepine-induced severe systemic hypersensitivity reaction with eosinophilia. Drug Intell Clin Pharm 1988 Oct; 22 (10): 783–784PubMed

52.

Cullinan S.A., Bower G.C. Acute pulmonary hypersensitivity to carbamazepine. Chest 1975 Oct; 68 (4): 580–581PubMedCrossRef

53.

Drory V.E., Korczyn A.D. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol 1993 Feb; 16 (1): 19–29PubMedCrossRef

54.

Friedmann P.S., Strickland I., Pirmohamed M., et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994 May; 130 (5): 598–604PubMedCrossRef

55.

Rzany B., Correia O., Kelly J.P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study: Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999 Jun 26; 353 (9171): 2190–2194PubMedCrossRef

56.

Leenutaphong V., Sivayathorn A., Suthipinittharm P., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993 Jun; 32 (6): 428–431PubMedCrossRef

57.

DeToledo J.C., Minagar A., Lowe M.R., et al. Skin eruption with gabapentin in a patient with repeated AED-induced Stevens-Johnson’s syndrome. Ther Drug Monit 1999 Feb; 21 (1): 137–138PubMedCrossRef

58.

Schwartz R.A. Toxic epidermal necrolysis. Cutis 1997 Mar; 59 (3): 123–128PubMed

59.

Breathnach S.M., McGibbon D.H., Ive F.A., et al. Carbamazepine (’Tegretol’) and toxic epidermal necrolysis: report of three cases with histopathological observations. Clin Exp Dermatol 1982 Nov; 7 (6): 585–591PubMedCrossRef

60.

Schaub N., Bircher A.J. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000 Feb; 55 (2): 191–193PubMedCrossRef

61.

Iannetti P., Raucci U., Zuccaro P., et al. Lamotrigine hypersensitivity in childhood epilepsy. Epilepsia 1998 May; 39 (5): 502–507PubMedCrossRef

62.

Sarzi-Puttini P., Panni B., Cazzola M., et al. Lamotrigine-induced lupus. Lupus 2000; 9 (7): 555–557PubMedCrossRef

63.

Fogh K., Mai J. Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). Seizure 1997 Feb; 6 (1): 63–65PubMedCrossRef

64.

Chaffin J.J., Davis S.M. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother 1997 Jun; 31 (6): 720–723PubMed

65.

Sterker M., Berrouschot J., Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995 Nov; 33 (11): 595–597PubMed

66.

Faught E., Morris G., Jacobson M., et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects: postmarketing antiepileptic drug survey (PADS) group. Epilepsia 1999; 40 (8): 1135–1140PubMedCrossRef

67.

Meinhold J.M., West D.P., Gurwich E., et al. Cutaneous reaction to lithium carbonate: a case report. J Clin Psychiatry 1980 Nov; 41 (11): 395–396PubMed

68.

Wakelin S.H., Lipscombe T., Orton D.I., et al. Lithium-induced follicular hyperkeratosis. Clin Exp Dermatol 1996 Jul; 21 (4): 296–298PubMedCrossRef

69.

Messenheimer J., Mullens E.L., Giorgi L., et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998 Apr; 18 (4): 281–296PubMedCrossRef

70.

Harth Y., Rapoport M. Photosensitivity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996 Apr; 14 (4): 252–259PubMedCrossRef

71.

Epstein J.H., Wintroub B.U. Photosensitivity due to drugs. Drugs 1985; 30 (1): 42–57PubMedCrossRef

72.

Warnock J.K., Knesevich J.W. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988; 145: 425–430PubMed

73.

Kimyai-Asadi A., Harris J.C., Nousari H.C. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999 Oct; 60 (10): 714–725PubMedCrossRef

74.

Benning T.L., McCormack K.M., Ingram P., et al. Microprobe analysis of chlorpromazine pigmentation. Arch Dermatol 1988; 124 (10): 1541–1544PubMedCrossRef

75.

Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996 Jul; 14 (3): 503–508PubMedCrossRef

76.

Stroud J.D. Drug-induced alopecia. Semin Dermatol 1985; 4: 29–34

77.

Warnock J.K. Psychotropic medication and drug-related alopecia. Psychosomatics 1991 Spr; 32 (2): 149–152PubMedCrossRef

78.

Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272–1285PubMedCrossRef

79.

Herbert A.A., Ralston J.P. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 2001; 62 Suppl. 14: 22–26

80.

Yoon Y., Jagoda A. New antiepileptic drugs and preparations. Emerg Med Clin North Am 2000; 18: 755–765PubMedCrossRef

81.

Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 Oct; 282 (5388): 490–493PubMedCrossRef

82.

Habif T.P. Clinical dermatology. 3rd ed. Chicago (IL): Mosby-Year Book, 1996

83.

Morkunas A.R., Miller M.B. Anticonvulsant hypersensitivity syndrome. Crit Care Clin 1997; 13: 727–739PubMedCrossRef

84.

Knowles S.R. Shapiro L.E., Shear N.H. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999 Dec; 21 (6): 489–501PubMedCrossRef

85.

Manders S.M. Serious and life-threatening drug eruptions. Am Fam Physician 1995 Jun; 51 (8): 1865–1872PubMed

86.

American Academy of Dermatology. Guidelines of care for cutaneous adverse drug reactions. J Am Acad Dermatol 1996; 35: 458–461CrossRef

87.

Warnock J.K., Morris D.W. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002; 3 (5): 329–339PubMedCrossRef

Titel: Adverse Cutaneous Reactions to Mood Stabilizers
verfasst von: Dr Julia K. Warnock
David W. Morris
Publikationsdatum: 01.01.2003
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 1/2003
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200304010-00003

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2003

Terbinafine

Can Thermal Lasers Promote Skin Wound Healing?

Cutaneous Drug Reaction Case Reports

Recognition and Management of the Cutaneous Manifestations of Celiac Disease